What are the Limitations of Current Drugs to Treat Pseudomonas Infections?
JUL 08, 2017 | CONTAGION® EDITORIAL STAFF
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains the limitations of the current drugs for the treatment of Pseudomonas infections.
Interview Transcript (slightly modified for readability)
“The limitation of the current drugs for the treatment of Pseudomonas [aeruginosa] is simple. Even our best anti-Pseudomonal agents that we currently had, at least until a couple of years ago, come with a 15% to 20% resistance rate. So, we run into a lot of situations where we can’t use our first-line agents to treat these infections, and we’re forced to use toxic suboptimal therapies instead.” DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512